explore -WSS

explore

author：hotspot 2025-09-03 09:22:46 - browse：498

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

knowledge

WSS

How state and local governments are sidelining science

Change Healthcare can notify patients about the breach, HHS says

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

FDA reorg will put new emphasis on investigations, sources say

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Woman returns to dialysis after doctors remove transplanted pig kidney

Activists slam private health insurers over coverage restrictions

NIH chief: government has fallen behind pharma on clinical trials

Medical leaders decry Supreme Court decision on affirmative action

Cancer diagnosis changes perspective doctor, former hospital CEO

Drug repurposing or repositioning? The language matters

NIH documents show early flaws of $1.6 billion long Covid program

In age of alternative facts, a scholarly course on calling out crap

Type 2 diabetes prevention programs work at large scale: study

entertainment

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca says CAR

FDA's Pazdur wants cancer trials to range beyond China alone

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

explore

hotspot

knowledge

explore